摘要
Livin,又称ML-IAP或KIAP是与肿瘤发生发展密切相关的凋亡抑制蛋白家族(inhibitor of apoposis proteins,IAPs)中的新成员,能够与内源IAP抑制剂SMAC和caspase-3,caspase-7,caspase-9结合,发挥抗细胞凋亡的作用。它特异性高表达于肿瘤组织而使肿瘤组织对放化疗作用变得耐受。近来,体内外研究表明下调或抑制Livin基因表达增加了肿瘤细胞凋亡率,抑制肿瘤细胞的增殖和集落形成能力,提高肿瘤细胞对化疗药物和放疗的敏感性。Livin将成为肿瘤治疗的潜在靶点。
Livin,also called melanoma inhibitor of apoptosis protein(IAP) or kidney IAP,is a novel member of the IAP family which relates with tumor development and progression. It could bind the endogenous IAP antagonist SMAC and caspase- 3, caspase -7, and caspase -9 to inhibit apoptosis. Livin is selectively expressed in the most common human neoplasms and appears to be involved in tumor cell resistance to chemotherapeutic agents and radiotherapy. Several studies in vitro and in vivo have demonstrated that down - regulation or inhibition of Livin expression increases the apoptotic rate, reduces tumor growth potential and sensitized tumor ceils to chemotherapeutic drugs and radiotherapy. Livin will be a new target for cancer treatment.
出处
《现代肿瘤医学》
CAS
2008年第6期1055-1058,共4页
Journal of Modern Oncology
基金
辽宁省教委科研项目基金(编号:05L506)